-transparent.png){kind=logo}
The aim of the study was to determine for the first time the response of systemic sclerosis (SSc) patients to treatment with intravenous immunoglobulin (IVIg). Three patients with progressive and rapidly deteriorating disease (mainly affecting the skin) were planned to receive six monthly courses of high-dose IVIg (2 g/kg). All had a thorough physical examination, clinical evaluation by the modified Rodnan total skin thickness score, and measurement of the titres of PM-Scl antibodies before and after the treatment, and before and after each treatment course. Two of the three patients received six IVIg courses as planned and no adverse effects or disease progression occurred during the therapy. The third patient received three courses, after which he developed renal failure and later died of sepsis. All three patients had a large decrease in their skin score after the treatment compared to that before the treatment. No modification of PM-Scl antibody titres was noted in any patient. Intravenous immunoglobulin (IVIg) may have a role in the treatment of SSc patients with rapidly deteriorating skin disease. The specific indications, as well as the safety of this treatment, should be further researched.
Y Levy, and
Y Sherer, and
P Langevitz, and
M Lorber, and
P Rotman, and
F Fabrizzi, and
Y Shoenfeld
May 2004,
Clinical and experimental dermatology,
Y Levy, and
Y Sherer, and
P Langevitz, and
M Lorber, and
P Rotman, and
F Fabrizzi, and
Y Shoenfeld
December 2012,
Arthritis and rheumatism,
Y Levy, and
Y Sherer, and
P Langevitz, and
M Lorber, and
P Rotman, and
F Fabrizzi, and
Y Shoenfeld
August 1951,
Journal of the American Medical Association,
Y Levy, and
Y Sherer, and
P Langevitz, and
M Lorber, and
P Rotman, and
F Fabrizzi, and
Y Shoenfeld
January 2014,
Scandinavian journal of rheumatology,
Y Levy, and
Y Sherer, and
P Langevitz, and
M Lorber, and
P Rotman, and
F Fabrizzi, and
Y Shoenfeld
July 1967,
Vox sanguinis,
Y Levy, and
Y Sherer, and
P Langevitz, and
M Lorber, and
P Rotman, and
F Fabrizzi, and
Y Shoenfeld
February 2001,
The Journal of rheumatology,
Y Levy, and
Y Sherer, and
P Langevitz, and
M Lorber, and
P Rotman, and
F Fabrizzi, and
Y Shoenfeld
January 2013,
Clinical and experimental rheumatology,
Y Levy, and
Y Sherer, and
P Langevitz, and
M Lorber, and
P Rotman, and
F Fabrizzi, and
Y Shoenfeld
February 2019,
Clinical immunology (Orlando, Fla.),
Y Levy, and
Y Sherer, and
P Langevitz, and
M Lorber, and
P Rotman, and
F Fabrizzi, and
Y Shoenfeld
March 2004,
Arthritis and rheumatism,
Y Levy, and
Y Sherer, and
P Langevitz, and
M Lorber, and
P Rotman, and
F Fabrizzi, and
Y Shoenfeld
January 2015,
Acta reumatologica portuguesa,
